Bazedoxifene (BioDeep_00000176461)
human metabolite blood metabolite
代谢物信息卡片
1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol
化学式: C30H34N2O3 (470.2569294)
中文名称: 巴多昔芬
谱图信息:
最多检出来源 Homo sapiens(blood) 92.86%
分子结构信息
SMILES: CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O
InChI: InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
描述信息
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03X - Other sex hormones and modulators of the genital system > G03XC - Selective estrogen receptor modulators
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
D050071 - Bone Density Conservation Agents
C1892 - Chemopreventive Agent
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:135947
- PubChem: 154257
- HMDB: HMDB0248898
- DrugBank: DB06401
- ChEMBL: CHEMBL46740
- Wikipedia: Bazedoxifene
- chemspider: 135921
- CAS: 198481-32-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Leyuan Chen, Gaiting Liu, Fancui Meng, Yu Shi, Zhennan Fang, Zhenyu Peng, Manjiang Wang, Wenfeng Gou, Wenbin Hou, Yiliang Li. Bazedoxifene analogs as potential WDHD1 degraders and antitumor agents: Synthesis, evaluation and molecular dynamics simulation studies.
Drug development research.
2024 Feb; 85(1):e22155. doi:
10.1002/ddr.22155. [PMID: 38349257] - Takashi Hara, Yasukazu Hijikata, Yukiko Matsubara, Norio Watanabe. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
The Cochrane database of systematic reviews.
2021 Jul; 7(?):CD013424. doi:
10.1002/14651858.cd013424.pub2. [PMID: 34231877] - Kara L Marlatt, Dragana Lovre, Robbie A Beyl, Chandra R Tate, Evelyn K Hayes, Charles F Burant, Eric Ravussin, Franck Mauvais-Jarvis. Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women.
European journal of endocrinology.
2020 Oct; 183(4):439-452. doi:
10.1530/eje-20-0619. [PMID: 32698159] - Karel Smetana, Daniel Rosel, Jan BrÁbek. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
In vivo (Athens, Greece).
2020 Sep; 34(5):3027-3028. doi:
10.21873/invivo.12135. [PMID: 32871847] - Karel Smetana, Jan Brábek. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
In vivo (Athens, Greece).
2020 Jun; 34(3 Suppl):1589-1592. doi:
10.21873/invivo.11947. [PMID: 32503815] - Hideki Masaki, Yasuo Imanishi, Hiroshi Naka, Yuki Nagata, Masafumi Kurajoh, Katsuhito Mori, Masanori Emoto, Takami Miki, Masaaki Inaba. Bazedoxifene improves renal function and increases renal phosphate excretion in patients with postmenopausal osteoporosis.
Journal of bone and mineral metabolism.
2020 May; 38(3):405-411. doi:
10.1007/s00774-019-01073-1. [PMID: 31897746] - Carol J Fabian, Lauren Nye, Kandy R Powers, Jennifer L Nydegger, Amy L Kreutzjans, Teresa A Phillips, Trina Metheny, Onalisa Winblad, Carola M Zalles, Christy R Hagan, Merit L Goodman, Byron J Gajewski, Devin C Koestler, Prabhakar Chalise, Bruce F Kimler. Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.
Cancer prevention research (Philadelphia, Pa.).
2019 10; 12(10):711-720. doi:
10.1158/1940-6207.capr-19-0315. [PMID: 31420361] - William McKeand, James Ermer, Joan Korth-Bradley. Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women.
Clinical pharmacology in drug development.
2018 11; 7(8):920-926. doi:
10.1002/cpdd.607. [PMID: 30144296] - Beibei Xu, Camille Allard, Ana I Alvarez-Mercado, Taylor Fuselier, Jun Ho Kim, Laurel A Coons, Sylvia C Hewitt, Fumihiko Urano, Kenneth S Korach, Ellis R Levin, Peter Arvan, Z Elizabeth Floyd, Franck Mauvais-Jarvis. Estrogens Promote Misfolded Proinsulin Degradation to Protect Insulin Production and Delay Diabetes.
Cell reports.
2018 07; 24(1):181-196. doi:
10.1016/j.celrep.2018.06.019. [PMID: 29972779] - Karen Lee Ann Chen, Xiaoji Liu, Yiru Chen Zhao, Kadriye Hieronymi, Gianluigi Rossi, Loretta Sue Auvil, Michael Welge, Colleen Bushell, Rebecca Lee Smith, Kathryn E Carlson, Sung Hoon Kim, John A Katzenellenbogen, Michael Joseph Miller, Zeynep Madak-Erdogan. Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal β-Glucuronidase Activity Without Impacting Overall Microbiome Community.
Scientific reports.
2018 05; 8(1):8166. doi:
10.1038/s41598-018-26506-1. [PMID: 29802368] - William McKeand, Susan Baird-Bellaire, James Ermer, Alain Patat. Pharmacokinetics and Safety of Bazedoxifene in Hepatically Impaired and Healthy Postmenopausal Women.
Clinical pharmacology in drug development.
2018 05; 7(4):365-372. doi:
10.1002/cpdd.438. [PMID: 29443456] - William McKeand, Susan Baird-Bellaire, James Ermer, Alain Patat. Pharmacokinetic Drug Interaction Study of Bazedoxifene and Ibuprofen.
Clinical pharmacology in drug development.
2018 05; 7(4):358-364. doi:
10.1002/cpdd.433. [PMID: 29389076] - William McKeand. Pharmacokinetics, Dose Proportionality, and Bioavailability of Bazedoxifene in Healthy Postmenopausal Women.
Clinical therapeutics.
2017 Sep; 39(9):1769-1779. doi:
10.1016/j.clinthera.2017.07.012. [PMID: 28756067] - Teresa Jover-Mengual, María Castelló-Ruiz, María C Burguete, María Jorques, Mikahela A López-Morales, Alicia Aliena-Valero, Andrés Jurado-Rodríguez, Salvador Pérez, José M Centeno, Francisco J Miranda, Enrique Alborch, Germán Torregrosa, Juan B Salom. Molecular mechanisms mediating the neuroprotective role of the selective estrogen receptor modulator, bazedoxifene, in acute ischemic stroke: A comparative study with 17β-estradiol.
The Journal of steroid biochemistry and molecular biology.
2017 07; 171(?):296-304. doi:
10.1016/j.jsbmb.2017.05.001. [PMID: 28479229] - Ippei Kanazawa, Tsutomu Tomita, Shun Miyazaki, Eiji Ozawa, Luis A Yamamoto, Toshitsugu Sugimoto. Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis and Accumulation of Advanced Glycation End Products by Reducing Oxidative Stress in MC3T3-E1 Cells.
Calcified tissue international.
2017 03; 100(3):286-297. doi:
10.1007/s00223-016-0211-x. [PMID: 27832315] - Karen Lee Ann Chen, Yiru Chen Zhao, Kadriye Hieronymi, Brandi Patricia Smith, Zeynep Madak-Erdogan. Bazedoxifene and conjugated estrogen combination maintains metabolic homeostasis and benefits liver health.
PloS one.
2017; 12(12):e0189911. doi:
10.1371/journal.pone.0189911. [PMID: 29267318] - Roberto Zarrabeitia, Luisa Ojeda-Fernandez, Lucia Recio, Carmelo Bernabéu, Jose A Parra, Virginia Albiñana, Luisa M Botella. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
Thrombosis and haemostasis.
2016 06; 115(6):1167-77. doi:
10.1160/th15-03-0239. [PMID: 26818701] - Elena M Umland, Lauren Karel, Nanette Santoro. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
Pharmacotherapy.
2016 05; 36(5):548-61. doi:
10.1002/phar.1749. [PMID: 27027527] - Annica Andersson, Angelina I Bernardi, Merja Nurkkala-Karlsson, Alexandra Stubelius, Louise Grahnemo, Claes Ohlsson, Hans Carlsten, Ulrika Islander. Suppression of Experimental Arthritis and Associated Bone Loss by a Tissue-Selective Estrogen Complex.
Endocrinology.
2016 Mar; 157(3):1013-20. doi:
10.1210/en.2015-1820. [PMID: 26745543] - Annica Andersson, Angelina I Bernardi, Alexandra Stubelius, Merja Nurkkala-Karlsson, Claes Ohlsson, Hans Carlsten, Ulrika Islander. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis.
Rheumatology (Oxford, England).
2016 Mar; 55(3):553-63. doi:
10.1093/rheumatology/kev355. [PMID: 26424839] - Sven O Skouby, Kaijie Pan, John R Thompson, Barry S Komm, Sebastian Mirkin. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
Menopause (New York, N.Y.).
2015 Jun; 22(6):640-9. doi:
10.1097/gme.0000000000000362. [PMID: 25405570] - John C Stevenson, Arkadi Chines, Kaijie Pan, Kelly A Ryan, Sebastian Mirkin. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.
The Journal of clinical endocrinology and metabolism.
2015 Jun; 100(6):2329-38. doi:
10.1210/jc.2014-2649. [PMID: 25894963] - Y Ishibashi, T Matsui, S Ueda, K Fukami, S Okuda, H Ohta, S Yamagishi. Bazedoxifene blocks AGEs-RAGE-induced superoxide generation and MCP-1 level in endothelial cells.
Climacteric : the journal of the International Menopause Society.
2015 Jun; 18(3):426-30. doi:
10.3109/13697137.2014.958073. [PMID: 25340263] - Susan Y Smith, Jacquelin Jolette, Luc Chouinard, Barry S Komm. The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey.
Journal of bone and mineral metabolism.
2015 Mar; 33(2):161-72. doi:
10.1007/s00774-014-0580-z. [PMID: 24633538] - Akira Itabashi, Kousei Yoh, Arkadi A Chines, Takami Miki, Masahiko Takada, Hiroshi Sato, Itsuo Gorai, Toshitsugu Sugimoto, Hideki Mizunuma, Hiroshi Ochi, Ginger D Constantine, Hiroaki Ohta. Bridging analysis of the efficacy and safety of bazedoxifene in Japanese and global populations of postmenopausal women with osteoporosis.
Journal of bone and mineral metabolism.
2015 Jan; 33(1):61-72. doi:
10.1007/s00774-013-0554-6. [PMID: 24714934] - María Castelló-Ruiz, Germán Torregrosa, María C Burguete, Francisco J Miranda, José M Centeno, Mikahela A López-Morales, Teresa Gasull, Enrique Alborch. The selective estrogen receptor modulator, bazedoxifene, reduces ischemic brain damage in male rat.
Neuroscience letters.
2014 Jul; 575(?):53-7. doi:
10.1016/j.neulet.2014.05.024. [PMID: 24861515] - S Adami, S Palacios, R Rizzoli, A B Levine, S Sutradhar, A A Chines. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status.
Climacteric : the journal of the International Menopause Society.
2014 Jun; 17(3):273-84. doi:
10.3109/13697137.2013.830605. [PMID: 23937421] - Thomas B Clarkson, Kelly F Ethun, Nicholas M Pajewski, Debbie Golden, Edison Floyd, Susan E Appt. Effects of bazedoxifene, conjugated equine estrogens, and a tissue-selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys.
Menopause (New York, N.Y.).
2014 Jan; 21(1):8-14. doi:
10.1097/gme.0b013e31829370e5. [PMID: 23676638] - J V Pinkerton, B S Komm, S Mirkin. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
Climacteric : the journal of the International Menopause Society.
2013 Dec; 16(6):618-28. doi:
10.3109/13697137.2013.810437. [PMID: 23805785] - Davide Gatti, Maurizio Rossini, Ignazio Sblendorio, Stefano Lello. Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.
Expert opinion on drug metabolism & toxicology.
2013 Jul; 9(7):883-92. doi:
10.1517/17425255.2013.794221. [PMID: 23621618] - Thomas B Clarkson, Kelly F Ethun, Haiying Chen, Debbie Golden, Edison Floyd, Susan E Appt. Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys.
Menopause (New York, N.Y.).
2013 Mar; 20(3):274-81. doi:
10.1097/gme.0b013e318271e59b. [PMID: 23435024] - Rick Perry, Carol A Thompson, J Nicole Earnhardt, David J Wright, Steven Bailey, Barry Komm, Mark A Cukierski. Renal tumors in male rats following long-term administration of bazedoxifene, a tissue-selective estrogen receptor modulator.
Toxicologic pathology.
2013; 41(7):1001-10. doi:
10.1177/0192623313477255. [PMID: 23416963] - Sean T Duggan, Kate McKeage. Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis.
Drugs.
2011 Nov; 71(16):2193-212. doi:
10.2165/11207420-000000000-00000. [PMID: 22035517] - Harry K Genant. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.
Menopause international.
2011 Jun; 17(2):44-9. doi:
10.1258/mi.2011.011011. [PMID: 21693498] - Gloria Bachmann, Uel Crosby, Robert A Feldman, Sheila Ronkin, Ginger D Constantine. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Menopause (New York, N.Y.).
2011 May; 18(5):508-14. doi:
10.1097/gme.0b013e3181fa358b. [PMID: 21289525] - Lars Rejnmark, Leif Mosekilde. New and emerging antiresorptive treatments in osteoporosis.
Current drug safety.
2011 Apr; 6(2):75-88. doi:
10.2174/157488611795684686. [PMID: 21524247] - Akira Itabashi, Kousei Yoh, Arkadi A Chines, Takami Miki, Masahiko Takada, Hiroshi Sato, Itsuo Gorai, Toshitsugu Sugimoto, Hideki Mizunuma, Hiroshi Ochi, Ginger D Constantine, Hiroaki Ohta. Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2011 Mar; 26(3):519-29. doi:
10.1002/jbmr.252. [PMID: 20839291] - L Xu, K-S Tsai, G S Kim, Y Wu, P Vincendon, A A Chines, G D Constantine. Efficacy and safety of bazedoxifene in postmenopausal Asian women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2011 Feb; 22(2):559-65. doi:
10.1007/s00198-010-1259-5. [PMID: 20535607] - Hisaya Kawate, Ryoichi Takayanagi. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis.
Clinical interventions in aging.
2011; 6(?):151-60. doi:
10.2147/cia.s15711. [PMID: 21753870] - Hiroaki Ohta. [Bazedoxifene as a new-generation SERM].
Clinical calcium.
2011 Jan; 21(1):34-42. doi:
clica11013442. [PMID: 21187592] - Enrico M Messalli, Cono Scaffa. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.
International journal of women's health.
2010 Aug; 1(?):11-20. doi:
10.2147/ijwh.s3894. [PMID: 21072271] - A Chandrasekaran, S Ahmad, L Shen, W DeMaio, T Hultin, J Scatina. Disposition of bazedoxifene in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2010 Aug; 40(8):578-85. doi:
10.3109/00498254.2010.492879. [PMID: 20528166] - Rogerio A Lobo, JoAnn V Pinkerton, Margery L S Gass, Maxine H Dorin, Sheila Ronkin, James H Pickar, Ginger Constantine. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
Fertility and sterility.
2009 Sep; 92(3):1025-1038. doi:
10.1016/j.fertnstert.2009.03.113. [PMID: 19635615] - Appavu Chandrasekaran, William E McKeand, Pamela Sullivan, William DeMaio, Randall Stoltz, JoAnn Scatina. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Drug metabolism and disposition: the biological fate of chemicals.
2009 Jun; 37(6):1219-25. doi:
10.1124/dmd.108.023861. [PMID: 19273530] - Annie W C Kung, Eva Y W Chu, Ling Xu. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis.
Expert opinion on pharmacotherapy.
2009 Jun; 10(8):1377-85. doi:
10.1517/14656560902980228. [PMID: 19445558] - Natalia O Kuchuk, Natasja M van Schoor, Saskia M Pluijm, Arkadi Chines, Paul Lips. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2009 Apr; 24(4):693-701. doi:
10.1359/jbmr.081209. [PMID: 19049341] - Yogendra Kharode, Peter V N Bodine, Christopher P Miller, C Richard Lyttle, Barry S Komm. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention.
Endocrinology.
2008 Dec; 149(12):6084-91. doi:
10.1210/en.2008-0817. [PMID: 18703623] - Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Giuseppe Martini, Ranuccio Nuti. Bazedoxifene for the prevention of postmenopausal osteoporosis.
Therapeutics and clinical risk management.
2008 Dec; 4(6):1229-42. doi:
10.2147/tcrm.s3476. [PMID: 19337430] - Luigi Gennari, Daniela Merlotti, Fabrizio Valleggi, Giuseppe Martini, Ranuccio Nuti. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.
Drugs & aging.
2007; 24(5):361-79. doi:
10.2165/00002512-200724050-00002. [PMID: 17503894] - Osamu Chaki. [Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene].
Clinical calcium.
2007 Jan; 17(1):30-5. doi:
clica07013035. [PMID: 17211091] - Osamu Chaki. [Next generation selective estrogen receptor modulators].
Clinical calcium.
2006 Jan; 16(1):145-52. doi:
clica0601145152. [PMID: 16397365] - Eric A Ariazi, Jennifer L Ariazi, Fernando Cordera, V Craig Jordan. Estrogen receptors as therapeutic targets in breast cancer.
Current topics in medicinal chemistry.
2006; 6(3):181-202. doi:
. [PMID: 16515478] - ". Lasofoxifene: CP 336156, CP-336156.
Drugs in R&D.
2005; 6(1):56-60. doi:
10.2165/00126839-200506010-00008. [PMID: 15801869] - B S Komm, C R Lyttle. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.
Annals of the New York Academy of Sciences.
2001 Dec; 949(?):317-26. doi:
10.1111/j.1749-6632.2001.tb04039.x. [PMID: 11795370]